MyMD Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Equity (Tables)

12 Months Ended

Dec. 31, 2017

Below is a summary of the gross proceeds to net proceeds calculation.

	Shares		$		$
Common Shares
Base Offering		1,667,000		2,000,400
Over-Allotment		122,500		147,000
Gross Proceeds					2,147,400
Underwriter/Gunnar Expenses
Discount				150,318
Legal Fees				60,000
Roadshow				1,783
Miscellaneous				34,005
Total					246,106
Akers Biosciences Expenses
Legal & Accounting				197,813
Registration/Regulatory				50,487
Total					248,300
Net Proceeds					1,652,994

Below is a summary of the gross proceeds to net proceeds calculation.

	Shares		$		$
Common Shares
Base Offering		1,448,400		2,027,760
Gross Proceeds						2,027,760
Underwriter/Gunnar Expenses
Discount				141,943
Legal Fees				50,000
Total						191,943
Akers Biosciences Expenses
Legal & Accounting				75,000
Filing Fees				500
Total						75,500
Net Proceeds						1,760,317

Below is a summary of the gross proceeds to net proceeds calculation.

	Public Offering - December 21, 2017
	Shares		$		$
Common Shares
Base Offering		15,500,000		2,325,000
Over-Allotment		6,000,000		900,000
Series B Preferred Shares
Base Offering		3,675		3,675,000
Gross Proceeds						6,900,000
Underwriter/Gunnar Expenses
Discount				483,000
Non-Accountable Allowance				60,000
Legal Fees				75,000
Roadshow				2,558
Miscellaneous				36,500
Total						657,058
Akers Biosciences Expenses
Legal & Accounting				160,000
Registration/Regulatory				17,356
Total						177,356
Net Proceeds						6,065,586

The expense is included in the Consolidated Statement of Operations and Comprehensive Loss for the year ending December 31, 2017 as follows: